Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page n+ e0 L- f7 _* N h
& D0 h1 }7 ]9 x" O
# M7 s* q j4 _Sub-category:0 R* P' h8 u t. ~' y
Molecular Targets
9 j: u' K5 F ` f' L0 }1 ~, q& D0 q$ U9 F" w" E G
5 \( V& C9 _) ^! d
Category:
; v1 I9 n# ?+ \6 g! }0 p4 HTumor Biology
1 g) p V8 P6 |! u$ l4 K! ?! w$ o! n. K1 T8 A! Z
5 V. N0 e+ `8 L- a4 V
Meeting:
$ @- Y) y* @* k% i4 S" y( {2011 ASCO Annual Meeting / e& s3 L6 n9 m1 \! P7 h P
$ D2 \+ Z( }6 h. |5 k2 [8 H* U
z2 t3 s! m" M# U. ^9 s1 D/ `Session Type and Session Title:# H \- G6 G' h R
Poster Discussion Session, Tumor Biology
- y# \* L. J: l C3 y
% N- A' {9 O6 s' Q2 v
# o( B5 o+ L: lAbstract No:
, w2 \6 Q. N- Z2 E3 p/ d10517 * ]" t# }: f9 o$ }9 w, m& \
# ?* \# ^0 I0 f" |
4 v8 O2 C3 j% q# Q. p6 j) A
Citation:5 D) d; E o. b' l; L H
J Clin Oncol 29: 2011 (suppl; abstr 10517) 0 K+ v7 g. z. ]% v3 ^, d2 j/ F7 }/ z
4 e# |0 |, c/ x# D
& A- {( x2 j' Y, n6 U0 J
Author(s):
) _2 U$ e: ]# ~) e- qJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
# U( l3 ?0 X; t' i$ C8 t" \' w, p& X% N
9 U# F) E! @/ L# p
$ _) k7 v; h) M: m/ ^& s# d* _: SAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
/ w$ K( t8 v" H$ E3 y, i5 c0 ]% Q$ B8 {, H6 ` A" G
Abstract Disclosures
4 V; o: a9 v! ]8 Z" Y$ S
" O% N/ U4 v& i% iAbstract:
, X* N' t+ b" b x0 L& f: Q
" Q/ O9 w# E( K& Y9 p! ] y4 [% e. C2 K( {! Y7 r6 T- R$ n
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.5 N' ~0 U# |. R
( d2 m* Y+ u# J @6 W$ N2 y7 n
; M4 `4 }# N- j) T" o4 }
|
显身卡
